PTGS2 and cancer: The potential therapeutic benefit of COX-2 inhibitors in a range of cancers is being seen as a great promise; however, since recent concerns about potential cardiotoxicity [16], [17] has generated an urgency to develop new inhibitors with a better risk/benefit ratio.